Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03690388) enrolled 187 people in total — 125 received a medicine called cabozantinib and 62 received a placebo (a dummy treatment with no active ingredient). The trial was measuring two main things: how long participants went without their disease getting worse (called "progression-free survival"), and how many participants had their disease visibly shrink or disappear (called "objective response rate"). The reported data shows that for progression-free survival — the time until the disease showed signs of growing or the person passed away — the figure for the cabozantinib group was listed as "NA" (meaning this particular summary number was not reported in the data submitted), while the placebo group's figure was 1.9 months. For the objective response rate, the reported data shows that 15% of participants in the cabozantinib group had their disease shrink or disappear (a complete or partial response), compared with 0% in the placebo group. It is also worth noting that of the 62 people in the placebo group, 36 did not complete the study, as was also the case for 36 of the 125 people in the cabozantinib group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38062732) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Thyroid Cancer Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of thyroid cancer called "differentiated thyroid cancer," confirmed by a lab test on a tissue or cell sample.
- Your cancer can be measured on a scan according to a standard set of medical guidelines.
- You have already been treated with radioactive iodine (a common thyroid cancer treatment) or your doctors have decided that treatment is not suitable for you.
- You have previously been treated with at least one of two specific targeted cancer drugs — lenvatinib or sorafenib — for your thyroid cancer (having taken up to two of these types of drugs is allowed).
- You are generally well enough to carry out light activity and care for yourself, as assessed by a standard health scoring system (confirm with trial site).
Who may not be able to join:
- You have previously been treated with cabozantinib, a certain type of BRAF-targeting drug, more than two targeted thyroid cancer drugs of a specific type, more than one immunotherapy treatment, or have had systemic chemotherapy.
- You have taken any targeted cancer tablet or capsule medicine within roughly the last 2–5 weeks before joining the trial.
- You have received an anticancer antibody treatment or chemotherapy within the last 4 weeks before joining the trial.
- You have had radiation therapy to a bone affected by cancer within the last 2 weeks, or any other radiation therapy within the last 4 weeks before joining the trial.
- You have cancer that has spread to the brain or the area around the brain, unless it has been successfully treated and is well controlled (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression Free Survival (PFS); Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.